Cryo-Cell International, Inc. (CCEL)
-0.38 (-5.37%)
Apr 16, 2024, 4:00 PM EDT - Market closed

Company Description

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use.

It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.

The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells.

It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Cryo-Cell International, Inc.
Cryo-Cell International logo
Country United States
Founded 1989
IPO Date Jan 21, 1997
Industry Medical Care Facilities
Sector Healthcare
Employees 82
CEO David I. Portnoy

Contact Details

700 Brooker Creek Blvd, Suite 1800
Oldsmar, Florida 34677
United States
Phone 813-749-2104

Stock Details

Ticker Symbol CCEL
Fiscal Year December - November
Reporting Currency USD
CIK Code 0000862692
CUSIP Number 228895108
ISIN Number US2288951088
Employer ID 22-3023093
SIC Code 8090

Key Executives

Name Position
David I. Portnoy Chairman and Co-Chief Executive Officer
Mark L. Portnoy Co-Chief Executive Officer and Director
Jill M. Taymans Chief Financial Officer and Vice President of Finance
Oleg Mikulinsky Chief Information Officer
Dr. Joanne Kurtzberg M.D. Medical Director and Member of Medical and Scientific Advisory Board

Latest SEC Filings

Date Type Title
Apr 15, 2024 10-Q Quarterly Report
Mar 26, 2024 8-K Current Report
Feb 28, 2024 10-K Annual Report
Oct 12, 2023 10-Q Quarterly Report
Oct 12, 2023 8-K Current Report
Sep 15, 2023 ARS Filing
Sep 14, 2023 DEF 14A Other definitive proxy statements
Aug 25, 2023 8-K Current Report
Jul 14, 2023 10-Q Quarterly Report
Apr 21, 2023 10-Q Quarterly Report